Elaine Thompson / AP

The results of a new clinical trial could revamp post-surgery treatment for people diagnosed with advanced melanoma, changing what had long been the standard protocol, per The Washington Post.

  • The trial looked at effectiveness of two immunotherapy drugs utilized after surgery to remove aggressive melanoma tumors. Yeroy has been the standard immunotherapy treatment, but it was put head-to-head with a new drug called Opdivo.
  • 71% of Opdivo users stayed cancer-free compared to 61% of those treated with Yervoy. Perhaps more importantly, users reacted better to Opdivo — only 5% of those on Opdivo discontinued their treatment due to side effects while 31% of Yervoy patients did so.
  • Why it matters: The combined safety and effectiveness of an immunotherapy drug like Opdivo is a big deal for advanced cancer treatment, considering the health risks of more traditional treatments like chemotherapy.
  • Not so fast: It's important to note the drug isn't a cure, it's a treatment designed to prevent relapse.

Go deeper

Updated 3 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Global: Total confirmed cases as of 4:30 p.m. ET: 21,020,216 — Total deaths: 761,393— Total recoveries: 13,048,303Map.
  2. U.S.: Total confirmed cases as of 4:30 p.m. ET: 5,289,323 — Total deaths: 167,948 — Total recoveries: 1,774,648 — Total tests: 64,831,306Map.
  3. Health: CDC: Survivors of COVID-19 have up to three months of immunity Fauci believes normalcy will return by "the end of 2021" with vaccine — The pandemic's toll on mental health.
  4. Business: How small businesses got stiffed — Unemployment starts moving in the right direction.
  5. Cities: Coronavirus pandemic dims NYC's annual 9/11 Tribute in Light.
  6. Politics: Biden signals fall strategy with new ads.

Harris: "Women are going to be a priority" in Biden administration

Sen. Kamala Harris at an event in Wilmington, Del. Photo: Drew Angerer/Getty Images

In her first sit-down interview since being named Joe Biden's running mate, Sen. Kamala Harris talked about what she'll do to fight for women if elected VP, and how the Democrats are thinking about voter turnout strategies ahead of November.

What they're saying: "In a Biden-Harris administration women are going to be a priority, understanding that women have many priorities and all of them must be acknowledged," Harris told The 19th*'s Errin Haines-Whack.

Facebook goes after Apple

Illustration: Lazaro Gamio/Axios

Facebook is seeking to force a face-off with Apple over its 30% in-app purchase commission fee, which Facebook suggests hurts small businesses struggling to get by during the pandemic.

The big picture: Facebook has never publicly gone after Apple, a key strategic partner, this aggressively. Both companies face antitrust scrutiny, which in Apple's case has centered on the very fee structure Facebook is now attacking.